VTGN

3.01

3.08% 0.09

Pre-mercato: 2.93 -0.08 -2.66%

Vistagen Therapeutics Inc (VTGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.92

Aprire:

$2.95

Volume 24 ore:

214.73K

Relative Volume:

0.77

Capitalizzazione di mercato:

$83.81M

Reddito:

$875.70K

Utile/perdita netta:

$-39.57M

Rapporto P/E:

-2.2424

EPS:

-1.3423

Flusso di cassa netto:

$-33.65M

1 W Prestazione:

+5.99%

1M Prestazione:

+20.40%

6M Prestazione:

-17.76%

1 anno Prestazione:

-34.85%

Intervallo 1D:

$2.90

$3.05

Intervallo di 1 settimana:

$2.83

$3.10

Portata 52W:

$2.22

$5.74

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Nome

Vistagen Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (685)

Telefono

650-577-3600

Indirizzo

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Dipendente

Cinguettio

@vistagen

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTGN Vistagen Therapeutics Inc	3.01	83.81M	875.70K	-39.57M	-33.65M	-1.3423
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-07	Aggiornamento	Jefferies	Hold → Buy
2023-08-07	Aggiornamento	Maxim Group	Hold → Buy
2022-07-22	Downgrade	Jefferies	Buy → Hold
2022-07-22	Downgrade	Robert W. Baird	Outperform → Neutral
2022-07-22	Downgrade	William Blair	Outperform → Mkt Perform
2021-05-20	Iniziato	Robert W. Baird	Outperform
2021-02-18	Iniziato	Jefferies	Buy
2021-01-04	Aggiornamento	William Blair	Mkt Perform → Outperform
2018-06-27	Iniziato	Maxim Group	Buy
2018-02-08	Reiterato	Chardan Capital Markets	Buy
2017-03-28	Iniziato	Maxim Group	Buy

Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

01:15 AM

Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World

01:15 AM

Jan 16, 2025

Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jan 16, 2025

Jan 15, 2025

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance

Jan 15, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada

Jan 14, 2025

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study - Investing.com

Jan 14, 2025

Jan 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Geode Capital Management LLC - Defense World

Jan 11, 2025

Jan 10, 2025

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - sharewise

Jan 10, 2025

Dec 27, 2024

HighTower Advisors LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Dec 27, 2024

Dec 19, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India

Dec 19, 2024

Dec 18, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges By Investing.com - Investing.com South Africa

Dec 18, 2024

Dec 12, 2024

Mental Disorder Treatment Market Innovations and Key Players: - openPR

Dec 12, 2024

PD-LID Market Growth to Accelerate in Forecast Period - openPR

Dec 12, 2024

Dec 11, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 11, 2024

Dec 10, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com

Dec 10, 2024

Nov 30, 2024

VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 27, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 22, 2024

VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India

Nov 22, 2024

Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024